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Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312 S271changed to serum-free labeling medium containing also chondrogenic
inducers. Expression of cartilage speciﬁc genes such as type I and II
collagen and proteoglycans were used to verify the chondrogenicity of
hBMSCs. Proteins in the CM harvested on day 2 and 14 of differentiation
were precipitated and combined at a 1:1 ratio. Each mixture was then
separated by 1D-SDS-PAGE and subjected to in-gel trypsin digestion
using an automatic digester. The resulting peptide mixtures were
analyzed by nanoscale liquid chromatography coupled on-line to an
LTQ-Orbitrap XLmass spectrometer and quantiﬁed using the MaxQuant
software.
Results: A progressive increase of type II collagen, agreccan and chon-
droitin-6-sulfate during the course of 14 days of differentiation was
detected by immunohistochemical assays, suggesting that hMSCs
maintain their chondrogenic capacity in SILAC medium. Using the
metabolic labeling strategy, we compared the secretomes at two
different time points of chondrogenesis. More than 1000 proteins were
identiﬁed with high conﬁdence parameters. 20% of them were previ-
ously known ECM-related proteins. Among these, 34 exhibited
a signiﬁcant modulation of their levels during the process of chondro-
genesis, including cartilage ECM proteins such as COMP, lumican, pro-
largin, ﬁbromodulin and matrix gla protein (MGP), which could be
involved in the organization and/or stabilization of cartilage matrix. All
these proteins were increased at day 14 of chondrogenesis. Finally,
pentraxin-related protein (PTX3), which plays a role in the regulation of
inﬂammatory response, resulted decreased at day 14.
Conclusions: This study was focused on characterizing the speciﬁc
modulations in the secretome of hBMSCs undergoing chondrogenesis
using the SILAC method. The identiﬁcation and quantiﬁcation of these
secreted proteins provide information about the changes in the ECM
synthesis during the differentiation process. Moreover, these ﬁndings
enhance our knowledge of extracellular regulation of this process and
allow the identiﬁcation of extracellular markers of chondrogenesis,
which might have potential value in cartilage regeneration strategies.
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Purpose: Recent works by our group provide evidences of the useful-
ness of proteomics techniques for anti- osteoarthritis (OA) drug
screening. The aim of this study is to identify protein markers for
monitoring chondroitin sulfate (CS) treatment by OA chondrocytes
secretome analysis using the iTRAQ technique.
Methods:Human articular chondrocytes (HACs) released from three OA
cartilages were cultured in DMEM supplemented with antibiotics and
10% FBS. At conﬂuence, OA chondrocytes were treated with 200 mg/mL
of CS (100% purity, bovine origin). 48 hours later, conditioned media
were collected and their proteins were concentrated and quantiﬁed.
Trypsin digestion and labeling with isobaric tags using iTRAQ reagents
were performed. Then, peptides from the two conditions (untreated,Table 1
Left panel: proteins increased by CS. Right panel: proteins decreased by CS.
Protein name Ratio p Value
Aggrecan core protein 1,57 0
Annexin A1 2,08 0,0144
Annexin A2 1,31 0,0365
Annexin A5 1,50 0,0091
Coiled-coil domain-containing
protein 80
1,77 0,0001
Connective tissue growth factor 1,84 0,0009
Extracellular sulfatase Sulf-1 2,11 0,0402
Glia-derived nexin 1,73 0
Hyaluronan and proteoglycan
link protein 1
1,74 0,0028
Target of Nesh-SH3 1,61 0,0019
Tenascin 1,71 0
Thrombospondin-1 1,90 0
Vascular cell adhesion protein 1 1,44 0,0039and CS-treated) were mixed, separated by reversed-phase liquid chro-
matography (LC) and analyzed by nanoscale reversed-phase LC coupled
to mass spectrometry (nLC-MALDI-MS/MS). The identiﬁcation and
quantiﬁcation of proteins (by calculating the different iTRAQ tag
intensities for each peptide) was carried out with Protein Pilot 4.0
software. Real-time, western blot, and immunohistochemistry analyses
were performed to validate our results.
Results: Database search (UniprotKB/Swissprot) allowed the identiﬁ-
cation of 260 different proteins secreted by OA chondrocytes. Among
them, we found 23 secreted proteins presenting statistically signiﬁcant
differences in abundance (p0.05) between treated and untreated
samples: 13 were increased by CS treatment and 10were decreased (see
Table 1). We considered only those proteins with a probability score
higher than 95%, a ratio 1.3 or -1.3, and an error factor <2. We have
successfully quantiﬁed the increase of extracellular matrix components
like aggrecan and other proteoglycans, and the decrease of degradative
enzymes such as cathepsins, caused by the administration of CS.
Annexins were increased by the drug while a glycolytic enzyme was
decreased. Finally we found altered several proteins involved in cell
adhesion and angiogenesis; among them we observed a strong CS-
dependent increase of an angiogenesis inhibitor, thrombospondin-1
(TSP1). Owing to the pivotal role of angiogenesis in OA physiopathology,
we decided to verify TSP1 gene expression level in CS-treated chon-
drocytes by real time-PCR analysis. TSP1 protein level was also veriﬁed
in chondrocyte conditioned media (secretome) and cellular extracts
(proteome) by western blot analyses, and in cartilage explants by
immunohistochemistry. The results obtained in the validation experi-
ments conﬁrmed the proteomics data.
Conclusions: We have found that isobaric tags using iTRAQ reagents is
one of the most promising strategies for accurate comparative proteo-
mics using HACs. We have generated a quantitative proﬁle of chon-
drocyte extracellular protein changes driven by CS in OA.
Demonstration of the anti-angiogenic action of CS might provide
a novel therapeutic approach for OA targeting. This study, however, has
been limited to an in vitro system. In the next futurewe hope to ﬁnd the
altered secreted proteins circulating in serum of OA patients treated
with CS.
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QUANTITATIVE PROTEOMICS OF DIFFERENT ZONES IN HUMAN
ARTICULAR CARTILAGE REVEALS EARLY CHANGES OF PROTEIN
DISTRIBUTION IN PRECLINICAL KNEE OSTEOARTHRITIS
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Purpose: The progress in proteomics technology development during
the last decade has contributed novel tools for detailed studies of the
composition of tissue extracellular matrix at the protein level including
cartilage and bone. We have used quantitative proteomics for a detailed
study of different zones in articular cartilage to increase our knowledge
of structure in relation to biology and function. In this work we studied
changes in protein abundance in very early osteoarthritic articular knee
cartilage samples in comparison to normal tissue.Protein name Ratio pValue
Alpha-actinin-4 -1,36 0,0338
Calreticulin -2,03 0,0144
Cathepsin D -1,34 0,0462
Cathepsin L1 -1,44 0,0251
Heat shock protein HSP 90-beta -1,77 0,0415
Moesin -1,50 0,038
Protein S100-A6 -1,98 0,0153
Pyruvate kinase isozymes M1/M2 -1,43 0,002
Retinol-binding protein 4 -1,44 0,026
Vimentin -1,42 0,0016
